Correspondence 0001493152-24-042638 from Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd.
Date: Oct. 28, 2024 · CIK: 0001595353 · Accession: 0001493152-24-042638

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-282753

Date

Oct. 28, 2024

Author

Galmed

Form

CORRESP

Company

Galmed Pharmaceuticals Ltd.

Letter

Galmed Pharmaceuticals Ltd.

Abba Hillel Road

Ramat Gan, Israel 5250608

October 28, 2024

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, DC 20549

RE: Galmed Pharmaceuticals Ltd. (CIK 0001595353)

Registration Statement No. 333-282753 on Form F-1 (the “Registration Statement”)

Ladies and Gentlemen:

Galmed Pharmaceuticals Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on October 28, 2024 at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling Gary Emmanuel at +1 212 801 9337. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

Very
truly yours,
Galmed
Pharmaceuticals LTD.

Show Raw Text

CORRESP
1
filename1.htm

Galmed
Pharmaceuticals Ltd.

16
Abba Hillel Road

Ramat
Gan, Israel 5250608

October
28, 2024

VIA
EDGAR

Securities
and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
DC 20549

    RE:
    Galmed
    Pharmaceuticals Ltd. (CIK 0001595353)

    Registration
    Statement No. 333-282753 on Form F-1 (the “Registration Statement”)

Ladies
and Gentlemen:

Galmed
Pharmaceuticals Ltd. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced
Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so
that it may become effective on October 28, 2024 at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The
undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel,
Greenberg Traurig, P.A., by calling Gary Emmanuel at +1 212 801 9337. The Company hereby authorizes Mr. Emmanuel to orally modify or
withdraw this request for acceleration.

    Very
    truly yours,

    Galmed
    Pharmaceuticals LTD.

    By:
    /s/
    Allen Baharaff

    Allen
    Baharaff

    Chief Executive Officer

SecProbe.io